Data published in PLOS ONE show Mymetics’ HIV-1 Innovative vaccine is safe and elicits strong immunogenicity
Epalinges, Switzerland, 21 February 2013
Results from a randomized study published in PLOS ONE1 today demonstrate that Mymetic’ innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation is a pioneer in the
development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases.
|Media Name||Media Type||Description||Download|
|130220 Mymetics Corporation - Press release 20 02 2013 - PLOSONE||Download|